^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | AVB-001 (IL-2 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Avenge Bio Receives FDA Fast Track Designation for AVB-001, a Novel Cell Therapy Leveraging the LOCOcyte™ Immunotherapy Platform
Published date:
10/02/2023
Excerpt:
Avenge Bio, Inc...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AVB-001 for treatment of patients with relapsed resistant/refractory ovarian cancer.
